| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(15 years from now) | |
Xcopri is owned by Sk Life.
Xcopri contains Cenobamate.
Xcopri has a total of 2 drug patents out of which 0 drug patents have expired.
Xcopri was authorised for market use on 10 March, 2020.
Xcopri is available in tablet;oral dosage forms.
Xcopri can be used as co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures.
Drug patent challenges can be filed against Xcopri from 10 March, 2024.
The generics of Xcopri are possible to be released after 16 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
Dosage: TABLET;ORAL
XCOPRI family patents
